Benjamin Cravatt joins ALNYLAM PHARMACEUTICALS (ALNY) board and files Form 3

Rhea-AI Filing Summary

ALNYLAM PHARMACEUTICALS, INC. director Benjamin Cravatt has filed an initial Form 3, which is a required statement of beneficial ownership for new insiders. This filing lists him as a director of the company but does not report any stock transactions or specific holdings in this excerpt.

Key Terms

Form 3, reportingPersons, beneficial ownership

3 terms

Form 3 regulatory

"INSIDER FILING DATA (Form 3)"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reportingPersons regulatory

""reportingPersons": [ { "name": "Cravatt Benjamin""

beneficial ownership financial

"This filing is an initial statement of beneficial ownership for new insiders."

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Cravatt Benjamin

(Last) (First) (Middle)

675 WEST KENDALL STREET

HENRI A. TERMEER SQUARE

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
06/01/2026

3. Issuer Name and Ticker or Trading Symbol
ALNYLAM PHARMACEUTICALS, INC. [ ALNY ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	Brett Budzinski, Attorney-in-fact for Benjamin Cravatt	06/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does the ALNY Form 3 filing by Benjamin Cravatt mean?

The Form 3 shows that Benjamin Cravatt is now an insider, serving as a director of ALNYLAM PHARMACEUTICALS, INC. It is an initial statement of beneficial ownership and, in this excerpt, does not list any stock transactions.

Does the ALNY Form 3 for Benjamin Cravatt show any share purchases or sales?

No, this Form 3 excerpt shows no reported transactions. The transaction summary lists zero buys, sells, exercises, gifts, or tax withholdings, meaning no insider trading activity is disclosed here.

What role does Benjamin Cravatt have at ALNYLAM PHARMACEUTICALS, INC. (ALNY)?

Benjamin Cravatt is identified as a director of ALNYLAM PHARMACEUTICALS, INC. The Form 3 marks him as a director, with no officer title or ten percent owner status indicated in this data.

Why are there no holdings or derivative positions in this ALNY Form 3 excerpt?

The provided Form 3 data shows no holding entries and an empty derivative summary. That means the excerpt does not list any common stock or derivative securities positions for Benjamin Cravatt in this particular view of the filing.

Does the ALNY Form 3 for Benjamin Cravatt indicate any Rule 10b5-1 trading plan?

The footnotes field in this excerpt is effectively empty, so there is no indication of a Rule 10b5-1 trading plan or other special arrangements disclosed here for Benjamin Cravatt.